ALGN
Align Technology
$173.76
▼ 4.6%Updated Today 7:15 PM ET
▲ Up 1.1% over the last 12 months
Market Cap
$13.04B
P/E
30.56x
Forward P/E (est.)
28.08x
ROE
10.7%
Revenue Growth
2.9%
EPS Growth
8.8%
Profit Margin
10.5%
FCF Yield
3.7%
Debt / Equity
0x
ROIC
10.0%
Interest Coverage
—
Current Ratio
1.39x
Dividend Yield
—
Implied Growth (rev. DCF)
5.0%
Rating Score
47/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ALGN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ALGN trades near $173.76, above its 50-day average ($173.75) and 200-day average ($159.95). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 50 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ALGN's is $6.97 (~4.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ALGN found buyers near $151.58 (support) and sellers near $185.00 (resistance); its 52-week range is $122.00–$208.31. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Align Technology (ALGN) is a large-cap company in the Health Care Supplies industry, part of the Health Care sector of the S&P 500, with a market value around $13.04B.
In its latest reported year it generated about $4.03B in revenue and $410.35M in net profit.
Our model rates ALGN Neutral (47/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
0.5%
Revenue moved from $3.95B in 2021 to $4.03B in 2025, a 0.5% compound annual growth rate. The most recent year was roughly flat (2.9%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
67.2%
Operating Margin
13.5%
Net Margin
10.2%
ROE
10.7%
Align Technology keeps about 10.5% of each sales dollar as net profit, with a 67.2% gross margin and 13.5% operating margin. Return on equity is 10.7% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 1.4x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$593.22M
Free Cash Flow
$490.78M
FCF Margin
12.2%
In the latest year Align Technology produced about $593.22M of operating cash flow and $490.78M of free cash flow after capital spending. That is a free-cash-flow yield of about 3.7% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
30.56x
P/S
3.21x
P/B
2.81x
EV / EBITDA
15.06x
ALGN trades at 30.6x trailing earnings (about 28.1x on estimated forward earnings), 3.2x sales, and 2.8x book value. Reverse-engineering today's price implies the market expects roughly 5.0% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ALGN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ALGN ranks #41 of 59 by our overall rating. It trades at a premium versus the sector on earnings (30.6x P/E vs. 25.4x median) with a lower return on equity (10.7% vs. 14.9%) and slower revenue growth (2.9% vs. 7.9%).
P/E vs sector
30.6x
median 25.4x
ROE vs sector
10.7%
median 14.9%
Growth vs sector
2.9%
median 7.9%
Sector rank
#41
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$124.10 – $202.47
vs. $173.76 today · expected CAGR -7% – 3%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.16B | $4.28B | $4.41B | $4.54B | $4.68B |
| Net income | $415.60M | $428.07M | $440.91M | $454.14M | $467.76M |
| EPS | $5.80 | $5.98 | $6.16 | $6.34 | $6.53 |
| Share price (low) | $110.26 | $113.57 | $116.97 | $120.48 | $124.10 |
| Share price (high) | $179.89 | $185.29 | $190.85 | $196.57 | $202.47 |
| CAGR (low–high) | -37% / 4% | -19% / 3% | -12% / 3% | -9% / 3% | -7% / 3% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ALGN:
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against ALGN:
- Revenue growth is slow (2.9%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 30.6x earnings, disappointing results could compress the multiple.
Growth risk — sluggish revenue (2.9%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Align Technology is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 30.6x earnings, which our model scores Neutral (47/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.